Research ArticlePsoriatic Arthritis
Open Access
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S. Rathmann, Susan R. Moriarty, Catherine L. Shuler, Hilde Carlier, Olivier Benichou and Philip J. Mease
The Journal of Rheumatology March 2018, 45 (3) 367-377; DOI: https://doi.org/10.3899/jrheum.170429
Désirée van der Heijde
From the Department of Rheumatology, Leiden University Medical Center, Leiden,
the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario,
Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo,
Japan; Eli Lilly and Company, Indianapolis, Indiana,
USA; Laboratoires Lilly
France, Neuilly,
France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington,
USA.
Dafna D. Gladman
Mitsumasa Kishimoto
Masato Okada
Suchitrita S. Rathmann
Susan R. Moriarty
Catherine L. Shuler
Hilde Carlier
Olivier Benichou
REFERENCES
- 1.↵
- 2.↵
- 3.↵
- 4.↵
- Lin AM,
- Rubin CJ,
- Khandpur R,
- Wang JY,
- Riblett M,
- Yalavarthi S,
- et al.
- 5.↵
- 6.↵
- Menon B,
- Gullick NJ,
- Walter GJ,
- Rajasekhar M,
- Garrood T,
- Evans HG,
- et al.
- 7.↵
- Leijten EF,
- van Kempen TS,
- Boes M,
- Michels-van Amelsfort JM,
- Hijnen D,
- Hartgring SA,
- et al.
- 8.↵
- Gossec L,
- Smolen JS,
- Ramiro S,
- de Wit M,
- Cutolo M,
- Dougados M,
- et al.
- 9.↵
- Liu L,
- Lu J,
- Allan BW,
- Tang Y,
- Tetreault J,
- Chow CK,
- et al.
- 10.↵
- Mease P,
- van der Heijde D,
- Ritchlin CT,
- Okada M,
- Cuchacovich RS,
- Shuler CL,
- et al.
- 11.↵Ixekizumab [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2017.
- 12.↵
- 13.↵
- 14.↵
- 15.↵
- National Psoriasis Foundation
- 16.↵
- 17.↵
- 18.↵
- Mease PJ,
- Woolley JM,
- Bitman B,
- Wang BC,
- Globe DR,
- Singh A
- 19.↵
- Prevoo ML,
- van’t Hof MA,
- Kuper HH,
- van Leeuwen MA,
- van de Putte LB,
- van Riel PL
- 20.↵
- 21.↵
- 22.↵
- Healy PJ,
- Helliwell PS
- 23.↵
- Helliwell PS,
- Firth J,
- Ibrahim GH,
- Melsom RD,
- Shah I,
- Turner DE
- 24.↵
- van der Heijde D,
- Sharp J,
- Wassenberg S,
- Gladman DD
- 25.↵
- 26.↵
- Bruynesteyn K,
- Boers M,
- Kostense P,
- van der Linden S,
- van der Heijde D
- 27.↵
- Strober B,
- Leonardi C,
- Papp K,
- Mrowietz U,
- Ohtsuki M,
- Bissonnette R,
- et al.
- 28.↵
- 29.↵
In this issue
The Journal of Rheumatology
Vol. 45, Issue 3
1 Mar 2018
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S. Rathmann, Susan R. Moriarty, Catherine L. Shuler, Hilde Carlier, Olivier Benichou, Philip J. Mease
The Journal of Rheumatology Mar 2018, 45 (3) 367-377; DOI: 10.3899/jrheum.170429
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S. Rathmann, Susan R. Moriarty, Catherine L. Shuler, Hilde Carlier, Olivier Benichou, Philip J. Mease
The Journal of Rheumatology Mar 2018, 45 (3) 367-377; DOI: 10.3899/jrheum.170429